Developer docs
API playgroundTry for free, no card

Search company profiles

ZEO ScientifiX

Full company profile

uuid002qi9v

Namestring
ZEO ScientifiX
Legal namestring
ZEO ScientifiX, Inc.
Company typeenum
Public
Founded yearint
2024
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDavie, United States
HQ citystring
Davie
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative biologics, extracellular vesicles, stem cell therapy, perinatal tissue products, cGMP biologics manufacturing
Industry2 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Regenerative Biologics Manufacturing
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Biologic Product Sales
TypeOne Time License
Description

Sale of regenerative biologics including stem cells, extracellular vesicles, Wharton's Jelly matrix, amniotic membrane patches, and autologous EV concentrates to physicians and healthcare providers for clinical use in regenerative medicine treatments.

zeoscientifix.com
2Masterclass Education Programs
TypeOne Time License
Description

Physician education and training programs including monthly Masterclasses at Nova Southeastern University ($200 per attendee) and virtual webinars. Expanded to patient-facing Masterclass programs hosted by physician partners.

zeoscientifix.com
Marketing channels12 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details2 tiers
1On-site Physician Masterclass
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$200 per attendee; includes educational presentations, legal compliance content, networking lunch, and facility tour

zeoscientifix.com
2Virtual Webinar
ModelFreemiumBilling cadencePay-as-you-go
Notes

Free registration for Zoom webinar sessions

zeoscientifix.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1DayZero
Description

Product line including DayZero Stem Cells and DayZero EV products derived from perinatal sources, including umbilical cord stem cells, Wharton's Jelly Matrix, and amniotic membrane patches.

zeoscientifix.com
+1 more record
Core offering1 text field

ZEO ScientifiX manufactures and sells regenerative biologic products—including umbilical cord-derived stem cells (DayZero™), Wharton's Jelly-derived extracellular vesicles, amniotic membrane patches, and an autologous platelet-derived EV system (PPX™)—to physicians and healthcare providers for use in orthopedics, wound care, pain management, and longevity therapies. The company also operates physician education Masterclass programs at Nova Southeastern University.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 500 physicians trained in regenerative medicine compliance through monthly Masterclass programs
+3 more records
Product overview1 text field

ZEO ScientifiX is a clinical-stage biotechnology company specializing in the development and controlled production of biologic materials for investigational, research, and regulated clinical applications. The company operates within established quality systems and regulatory frameworks, supporting scientific collaboration with healthcare professionals and institutions. Their product portfolio centers on regenerative biologics including the DayZero™ line of products derived from perinatal sources (umbilical cord stem cells and Wharton's Jelly Matrix), amniotic membrane patches, and the Patient Pure X™ (PPX™) autologous system. DayZero™ biologics are collected within hours of delivery, screened, documented, processed in an FDA-registered cGMP facility, and cryopreserved to preserve potency. The company also offers physician education through Masterclass programs and maintains a provider directory connecting physicians with their biologic products.

Product and service5 records
1DayZero™ Stem Cells
CategoryRegenerative Biologics
Description

Umbilical cord-derived allogeneic stem cells offered to physicians in vial and IV bag formats for use in orthopedics, pain management, and advanced wound care. Cells are ethically sourced, screened, and processed in an FDA-registered cGMP facility.

2DayZero™ EV (Wharton's Jelly Matrix)
CategoryRegenerative Biologics
Description

Gelatinous scaffold combining natural collagen and hyaluronic-rich matrix with a dense extracellular vesicle payload, offered to physicians in 50B, 100B, and 200B EV vial sizes for regenerative procedures.

3Amniotic-Membrane Patches
CategoryRegenerative Biologics
Description

Biological extracellular membrane sheets that retain endogenous growth factors and an intact collagen network, used by physicians as a dressing for surgical closure and chronic wound treatment.

4Patient Pure X™ (PPX™)
CategoryRegenerative Biologics
Description

Autologous extracellular vesicle system in which the patient's own platelets are collected chair-side and processed in an FDA-registered cGMP facility using a proprietary centrifugation sequence to concentrate platelet-derived EVs; offered to physicians in 100B, 200B, and 400B vial sizes.

5Physician Masterclass Program
CategoryMedical Education & Training
Description

Paid educational and training program for physicians on regenerative medicine compliance, clinical applications, and product use, delivered monthly at Nova Southeastern University ($200 per attendee) and via free virtual Zoom webinars.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

MOU for exclusive scientific and biologics strategic collaboration positioning ZEO as the core supplier of advanced biologic therapeutics for Regen Therapy's platform of 3,000+ clinics and 24,000 practitioners. Creates vertically integrated ecosystem combining clinical delivery, telemedicine infrastructure, and biologic product development for regenerative and longevity care at scale.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

Strategic partnership with Stealth Health to deploy white-label telemedicine and longevity services across Regen Therapy's clinical network. Enables clinics to offer physician-guided consultations, hormone replacement therapy, GLP-1 weight management programs, and data-driven longevity protocols.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-03-31
Description

Official Regenerative Medicine Educational Partner for A4M's Longevity SpringFest 2026 and ongoing programming. ZEO serves as the 'official arm of education' for regenerative medicine, leading specialized full-day Masterclass and gaining direct access to A4M's network of 26,000 physicians and practitioners across 120 nations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

Three-way strategic partnership to manufacture and commercialize Cytora's allogeneic human oral mucosal stem cell therapy (CytoraStem™) in the U.S. ZEO handles exclusive U.S. commercialization, initially leveraging Florida's SB 1768 for wound care indications while pursuing FDA Phase 2b clinical trials for diabetic foot ulcers.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-07
Description

Exclusive U.S. GMP manufacturing partner from Princeton, New Jersey facility for Cytora's allogeneic stem cell therapy. Collaboration involves manufacturing, clinical trials, and market access for diabetic foot ulcer treatment.

6Exotropin
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-11-13
Description

Joint venture to launch solution addressing hair loss unmet need. Combines ZEO's biologic products with Exotropin's expertise.

zeoscientifix.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-10-04
Description

Partnership with multi-state healthcare provider operating 75 clinics with over 750 clinical personnel treating 1,500-2,000 patients monthly. Aims to advance ZEO's clinical trial programs including Phase 2 trials for flagship product Zofin™, leveraging Physicians Group's network and diverse patient population for musculoskeletal and other health indications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Operating out of Nova Southeastern University's Center of Collaborative Research, a $100 Million research facility. Hosts monthly Masterclass training programs at Alvin Sherman Library location.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as strategic partner on website. Founder Elizabeth Parrish serves on ZEO's Medical Advisory Board and is collaborating on XPRIZE Healthspan competition team.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as strategic partner on website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as strategic partner on website. Dr. Michael Swartzon from Baptist Health serves on Medical Advisory Board.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as strategic partner. Dr. Bryan T. Kelly (President & CEO, Surgeon-in-Chief Emeritus) and Dr. Riley J. Williams III serve on Medical Advisory Board.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as strategic partner. Dr. Laith M. Jazrawi (Chief, Division of Sports Medicine) serves on Medical Advisory Board.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as strategic partner on website.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as strategic partner. Dr. George C. Shapiro was co-founder and Chief Medical Innovation Officer of Fountain Life.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Commercial-stage cell therapy company developing mesenchymal stem cell-based treatments for inflammatory and age-related diseases. Comparable in biologic/cellular therapy category and musculoskeletal/regenerative indications, but at much later stage and broader scale.

TypeOthers
Description

Longevity and preventive health platform founded/co-founded by ZEO's CMO Dr. George C. Shapiro. Closely aligned in longevity and regenerative medicine patient positioning, providing both customer overlap and brand adjacency.

TypeDirect peer
Description

Specializes in perinatal-derived exosome and stem cell products (including Wharton's Jelly-derived EVs) sold to physicians for regenerative applications. Nearly identical upstream sourcing and downstream distribution model to ZEO's DayZero line.

TypeEmerging player
Description

Clinical-stage company developing mitochondrial cell therapies for age-related and rare diseases. Listed ZEO strategic partner with overlapping regenerative medicine and longevity thesis, though differentiated by mitochondrial augmentation.

TypeDirect peer
Description

U.S.-based regenerative medicine company developing exosome and stem cell biologic products sold through physicians. Closely comparable product portfolio (EV/exosome therapeutics), physician-channel GTM, and regulatory positioning to ZEO.

6Pluristem Therapeutics
TypeBroad incumbent
Description

Develops placenta-derived allogeneic cell therapies for musculoskeletal, wound healing, and regenerative indications. Highly comparable in source material (perinatal), manufacturing approach (cGMP biologics), and clinical indications.

TypeOthers
Description

Clinical delivery and telemedicine platform operating 3,000+ clinics and 24,000 practitioners. ZEO's exclusive biologics distribution partner, making it the dominant channel through which ZEO products reach end providers.

TypeEmerging player
Description

Longevity-focused biotech developing gene and cell therapies to address biological aging. ZEO strategic partner and XPRIZE Healthspan collaborator with strongly overlapping aging/longevity therapeutic ambitions.

9AgeX Therapeutics
TypeBroad incumbent
Description

Clinical-stage biotechnology company focused on regenerative medicine and aging-related cellular therapies. Comparable in therapeutic focus on biological mechanisms of aging and use of stem cell-derived platforms, though larger and more capital-intensive.

TypeEmerging player
Description

Developer of allogeneic oral mucosal stem cell therapy (CytoraStem) for diabetic foot ulcers. ZEO's strategic partner for U.S. commercialization and Phase 2b trials; directly comparable in regenerative medicine and wound care focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ZEO ScientifiX

Regenerative Biologics Manufacturingzeoscientifix.com

ZEO ScientifiX firmographics

Firmographics
Name
ZEO ScientifiX
Legal name
ZEO ScientifiX, Inc.
Website
https://zeoscientifix.com
Company type
Public
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

ZEO ScientifiX industry classification

Industry
Product category
Regenerative Biologics Manufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative biologics
  • Extracellular vesicles
  • Stem cell therapy
  • Perinatal tissue products
  • CGMP biologics manufacturing

Where ZEO ScientifiX is headquartered

Location

Headquarters

HQ city
Davie
HQ country
United States
HQ region
North America

Offices3 records

Markets served

ZEO ScientifiX business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Biologic Product Sales: Sale of regenerative biologics including stem cells, extracellular vesicles, Wharton's Jelly matrix, amniotic membrane patches, and autologous EV concentrates to physicians and healthcare providers for clinical use in regenerative medicine treatments.
  2. Masterclass Education Programs: Physician education and training programs including monthly Masterclasses at Nova Southeastern University ($200 per attendee) and virtual webinars. Expanded to patient-facing Masterclass programs hosted by physician partners.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goOn-site Physician Masterclass
FreemiumPay-as-you-goVirtual Webinar

Go-to-market motion3 records

Distribution channels3 records

Marketing channels12 records

ZEO ScientifiX product offering

Product offering

Core offering

ZEO ScientifiX manufactures and sells regenerative biologic products—including umbilical cord-derived stem cells (DayZero™), Wharton's Jelly-derived extracellular vesicles, amniotic membrane patches, and an autologous platelet-derived EV system (PPX™)—to physicians and healthcare providers for use in orthopedics, wound care, pain management, and longevity therapies. The company also operates physician education Masterclass programs at Nova Southeastern University.

Product overview

ZEO ScientifiX is a clinical-stage biotechnology company specializing in the development and controlled production of biologic materials for investigational, research, and regulated clinical applications. The company operates within established quality systems and regulatory frameworks, supporting scientific collaboration with healthcare professionals and institutions. Their product portfolio centers on regenerative biologics including the DayZero™ line of products derived from perinatal sources (umbilical cord stem cells and Wharton's Jelly Matrix), amniotic membrane patches, and the Patient Pure X™ (PPX™) autologous system. DayZero™ biologics are collected within hours of delivery, screened, documented, processed in an FDA-registered cGMP facility, and cryopreserved to preserve potency. The company also offers physician education through Masterclass programs and maintains a provider directory connecting physicians with their biologic products.

Differentiator

Problem solved

Functional benefit

Brands

  • DayZero: Product line including DayZero Stem Cells and DayZero EV products derived from perinatal sources, including umbilical cord stem cells, Wharton's Jelly Matrix, and amniotic membrane patches.
  • Patient Pure X (PPX)

Products and services

  • DayZero™ Stem Cells Umbilical cord-derived allogeneic stem cells offered to physicians in vial and IV bag formats for use in orthopedics, pain management, and advanced wound care. Cells are ethically sourced, screened, and processed in an FDA-registered cGMP facility.
  • DayZero™ EV (Wharton's Jelly Matrix) Gelatinous scaffold combining natural collagen and hyaluronic-rich matrix with a dense extracellular vesicle payload, offered to physicians in 50B, 100B, and 200B EV vial sizes for regenerative procedures.
  • Amniotic-Membrane Patches Biological extracellular membrane sheets that retain endogenous growth factors and an intact collagen network, used by physicians as a dressing for surgical closure and chronic wound treatment.
  • Patient Pure X™ (PPX™) Autologous extracellular vesicle system in which the patient's own platelets are collected chair-side and processed in an FDA-registered cGMP facility using a proprietary centrifugation sequence to concentrate platelet-derived EVs; offered to physicians in 100B, 200B, and 400B vial sizes.
  • Physician Masterclass Program Paid educational and training program for physicians on regenerative medicine compliance, clinical applications, and product use, delivered monthly at Nova Southeastern University ($200 per attendee) and via free virtual Zoom webinars.

Quantifiable outcome

  • Over 500 physicians trained in regenerative medicine compliance through monthly Masterclass programs
  • +3 more outcomes

Companies that use ZEO ScientifiX

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

ZEO ScientifiX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

ZEO ScientifiX partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core, minor and major.

  • Regen TherapycoreStrategic or Co-development Partner · 9 April 2026MOU for exclusive scientific and biologics strategic collaboration positioning ZEO as the core supplier of advanced biologic therapeutics for Regen Therapy's platform of 3,000+ clinics and 24,000 practitioners. Creates vertically integrated ecosystem combining clinical delivery, telemedicine infrastructure, and biologic product development for regenerative and longevity care at scale.
  • Stealth HealthcoreStrategic or Co-development Partner · 9 April 2026Strategic partnership with Stealth Health to deploy white-label telemedicine and longevity services across Regen Therapy's clinical network. Enables clinics to offer physician-guided consultations, hormone replacement therapy, GLP-1 weight management programs, and data-driven longevity protocols.
  • American Academy of Anti-Aging Medicine (A4M)coreGTM or Marketing Partner · 31 March 2026Official Regenerative Medicine Educational Partner for A4M's Longevity SpringFest 2026 and ongoing programming. ZEO serves as the 'official arm of education' for regenerative medicine, leading specialized full-day Masterclass and gaining direct access to A4M's network of 26,000 physicians and practitioners across 120 nations.
  • Cytora TherapeuticscoreStrategic or Co-development Partner · 7 January 2026Three-way strategic partnership to manufacture and commercialize Cytora's allogeneic human oral mucosal stem cell therapy (CytoraStem™) in the U.S. ZEO handles exclusive U.S. commercialization, initially leveraging Florida's SB 1768 for wound care indications while pursuing FDA Phase 2b clinical trials for diabetic foot ulcers.
  • Made ScientificcoreTechnology or Integration · 7 January 2026Exclusive U.S. GMP manufacturing partner from Princeton, New Jersey facility for Cytora's allogeneic stem cell therapy. Collaboration involves manufacturing, clinical trials, and market access for diabetic foot ulcer treatment.
  • ExotropinminorStrategic or Co-development Partner · 13 November 2024Joint venture to launch solution addressing hair loss unmet need. Combines ZEO's biologic products with Exotropin's expertise.
  • Physicians Group, LLCmajorStrategic or Co-development Partner · 4 October 2024Partnership with multi-state healthcare provider operating 75 clinics with over 750 clinical personnel treating 1,500-2,000 patients monthly. Aims to advance ZEO's clinical trial programs including Phase 2 trials for flagship product Zofin™, leveraging Physicians Group's network and diverse patient population for musculoskeletal and other health indications.
  • Nova Southeastern UniversitycoreStrategic or Co-development PartnerOperating out of Nova Southeastern University's Center of Collaborative Research, a $100 Million research facility. Hosts monthly Masterclass training programs at Alvin Sherman Library location.
  • BioViva ScienceminorStrategic or Co-development PartnerListed as strategic partner on website. Founder Elizabeth Parrish serves on ZEO's Medical Advisory Board and is collaborating on XPRIZE Healthspan competition team.
  • Minovia TherapeuticsminorStrategic or Co-development PartnerListed as strategic partner on website.
  • Baptist Health South FloridaminorStrategic or Co-development PartnerListed as strategic partner on website. Dr. Michael Swartzon from Baptist Health serves on Medical Advisory Board.
  • Hospital for Special Surgery (HSS)minorStrategic or Co-development PartnerListed as strategic partner. Dr. Bryan T. Kelly (President & CEO, Surgeon-in-Chief Emeritus) and Dr. Riley J. Williams III serve on Medical Advisory Board.
  • NYU Langone HealthminorStrategic or Co-development PartnerListed as strategic partner. Dr. Laith M. Jazrawi (Chief, Division of Sports Medicine) serves on Medical Advisory Board.
  • Mount Sinai Medical CenterminorStrategic or Co-development PartnerListed as strategic partner on website.
  • Fountain LifeminorStrategic or Co-development PartnerListed as strategic partner. Dr. George C. Shapiro was co-founder and Chief Medical Innovation Officer of Fountain Life.

Scale indicators16 records

Recent moves8 records

Expansion highlights7 records

ZEO ScientifiX competitors and assessment

Company assessment

Broad incumbents

  • Mesoblast: Commercial-stage cell therapy company developing mesenchymal stem cell-based treatments for inflammatory and age-related diseases. Comparable in biologic/cellular therapy category and musculoskeletal/regenerative indications, but at much later stage and broader scale.
  • Pluristem Therapeutics: Develops placenta-derived allogeneic cell therapies for musculoskeletal, wound healing, and regenerative indications. Highly comparable in source material (perinatal), manufacturing approach (cGMP biologics), and clinical indications.
  • AgeX Therapeutics: Clinical-stage biotechnology company focused on regenerative medicine and aging-related cellular therapies. Comparable in therapeutic focus on biological mechanisms of aging and use of stem cell-derived platforms, though larger and more capital-intensive.

Others

  • Fountain Life: Longevity and preventive health platform founded/co-founded by ZEO's CMO Dr. George C. Shapiro. Closely aligned in longevity and regenerative medicine patient positioning, providing both customer overlap and brand adjacency.
  • Regen Therapy: Clinical delivery and telemedicine platform operating 3,000+ clinics and 24,000 practitioners. ZEO's exclusive biologics distribution partner, making it the dominant channel through which ZEO products reach end providers.

Direct peers

  • Kimera Labs: Specializes in perinatal-derived exosome and stem cell products (including Wharton's Jelly-derived EVs) sold to physicians for regenerative applications. Nearly identical upstream sourcing and downstream distribution model to ZEO's DayZero line.
  • Direct Biologics: U.S.-based regenerative medicine company developing exosome and stem cell biologic products sold through physicians. Closely comparable product portfolio (EV/exosome therapeutics), physician-channel GTM, and regulatory positioning to ZEO.

Emerging players

  • Minovia Therapeutics: Clinical-stage company developing mitochondrial cell therapies for age-related and rare diseases. Listed ZEO strategic partner with overlapping regenerative medicine and longevity thesis, though differentiated by mitochondrial augmentation.
  • BioViva Science: Longevity-focused biotech developing gene and cell therapies to address biological aging. ZEO strategic partner and XPRIZE Healthspan collaborator with strongly overlapping aging/longevity therapeutic ambitions.
  • Cytora Therapeutics: Developer of allogeneic oral mucosal stem cell therapy (CytoraStem) for diabetic foot ulcers. ZEO's strategic partner for U.S. commercialization and Phase 2b trials; directly comparable in regenerative medicine and wound care focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ZEO ScientifiX social profiles

Digital presence

ZEO ScientifiX compliance and trust

Trust signal

Compliance3 records

ZEO ScientifiX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ZEO ScientifiX leadership team

Management profile

Number of profiles

Profiles10 records

ZEO ScientifiX funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ZEO ScientifiX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZEO ScientifiX

What does ZEO ScientifiX do?

ZEO ScientifiX manufactures and sells regenerative biologic products—including umbilical cord-derived stem cells (DayZero™), Wharton's Jelly-derived extracellular vesicles, amniotic membrane patches, and an autologous platelet-derived EV system (PPX™)—to physicians and healthcare providers for use in orthopedics, wound care, pain management, and longevity therapies. The company also operates physician education Masterclass programs at Nova Southeastern University.

Is ZEO ScientifiX a public or private company?

ZEO ScientifiX is a public company. It is classified as public and is currently operating.

When was ZEO ScientifiX founded?

ZEO ScientifiX was founded in 2024. It employs 11 to 50 people.

Where is ZEO ScientifiX based?

ZEO ScientifiX is headquartered in Davie, United States, in the North America region.

How does ZEO ScientifiX make money?

Two revenue lines are on record. Biologic Product Sales are the primary driver. The others are masterclass Education Programs.

Who are ZEO ScientifiX's main competitors?

Broad incumbents on record are Mesoblast, Pluristem Therapeutics and AgeX Therapeutics. Others are Fountain Life and Regen Therapy. Direct peers are Kimera Labs and Direct Biologics. Emerging players are Minovia Therapeutics, BioViva Science and Cytora Therapeutics.

Does ZEO ScientifiX have an API?

No public API is recorded for ZEO ScientifiX.

What industry is ZEO ScientifiX in?

ZEO ScientifiX's product category is Regenerative Biologics Manufacturing. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaPluri Inc. (PLUR) Discusses Commercialization Strategy, ZEO ScientifiX Transaction and Financial Flexibility TranscriptPluri Inc. CEO Yaky Yanay presented the company's commercialization strategy and the ZEO ScientifiX transaction in a webinar. Pluri, a regenerative medicine and cell-therapy firm, has treated hundreds of patients and completed two Phase III studies in the U.S. and Europe. The company outlined its plans for the coming year.Insider Trading & Hedge Fund DataPluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial PlatformPluri and ZEO ScientifiX announced a partnership to expand their U.S. manufacturing and commercial platform for regenerative medicine. ZEO will acquire 50% of Pluri, and the deal is expected to close in Q4 2026. The companies aim to combine Pluri's cell technology with ZEO's biologics manufacturing and physician network.InvestegatePluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial PlatformPluri and ZEO ScientifiX announced a strategic partnership to expand their U.S. manufacturing and commercialization platform for regenerative medicine. Pluri will grant ZEO rights to its manufacturing technology, and ZEO will issue shares representing 50% of its outstanding stock. Closing is expected in Q4 2026, subject to conditions.EIN PresswirePluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative MedicinePluri and ZEO ScientifiX announced a strategic partnership to expand their U.S. manufacturing and commercialization platform for regenerative medicine. Pluri will grant ZEO rights to its manufacturing technology, and ZEO will issue shares representing 50% of its stock after closing. The transaction is expected to close in the fourth quarter of 2026.EIN PresswirePluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative MedicinePluri and ZEO ScientifiX announced a partnership to expand their U.S. manufacturing and commercialization platform for regenerative medicine. Pluri will grant ZEO rights to its manufacturing technology, and ZEO will issue shares representing 50% of its stock after closing. The transaction is expected to close in Q4 2026.FinancialContent Business PageZEO ScientifiX Launches First-of-Its-Kind ZEO Xperience, a Three-Day Immersive Regenerative Medicine Experience for Healthcare ProfessionalsZEO ScientifiX announced the launch of ZEO Xperience, a three-day immersive educational event for healthcare professionals focused on regenerative medicine, scheduled for October 23-25, 2026 at Pier Sixty-Six Resort in Fort Lauderdale, Florida. The event combines evidence-based scientific education, hands-on clinical training, practice growth strategies, and longevity experiences for physicians, nurse practitioners, physician assistants, nurses, chiropractors, dentists, and podiatrists. The inaugural event represents the company's latest milestone in advancing physician education and supporting the responsible adoption of regenerative biologic technologies.Stock TitanZEO ScientifiX Launches 3-Day Regenerative Medicine EventZEO ScientifiX announced the launch of ZEO Xperience, an inaugural three-day immersive educational event for healthcare professionals focused on regenerative medicine, scheduled for October 23-25, 2026 at the Pier Sixty-Six Resort in Fort Lauderdale, Florida. The event will combine evidence-based scientific education, hands-on clinical training, business development strategies, and interactive wellness experiences designed to help healthcare professionals integrate advanced biologic therapies into their practices. This launch represents another milestone in ZEO ScientifiX's commitment to advancing physician education and the responsible adoption of regenerative biologic technologies.FinancialContent Business PageZEO ScientifiX Strengthens South Florida's Growing Biotechnology Ecosystem Through Regenerative Medicine InnovationZEO ScientifiX, Inc., a clinical-stage biopharmaceutical company focused on regenerative biologics, is expanding its operations from Nova Southeastern University's Center for Collaborative Research in Davie, Florida, as part of the state's emerging life sciences hub. The company is investing in physician education initiatives, including Master Classes, webinars, and a Medical Advisory Board, to strengthen the connection between scientific advancement and clinical practice. Florida has attracted increasing biotechnology investment, talent, and research institutions, with South Florida developing into a healthcare and biotechnology corridor.Stock TitanZEO ScientifiX Expands Regenerative Biologics ResearchZEO ScientifiX, Inc. is expanding its presence within South Florida's biotechnology ecosystem through regenerative biologic research, development, physician education, and scientific collaboration initiatives. The company operates from Nova Southeastern University's Center for Collaborative Research in Davie, Florida, positioning itself within the state's growing life sciences hub. ZEO ScientifiX intends to continue expanding its scientific and educational programs while strengthening relationships across the medical community.FinancialContent Business PageZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026ZEO ScientifiX reported revenue growth of 124.6% to $2.58 million for the quarter ended April 30, 2026, and 79.9% to $4.03 million for the six-month period, compared to the same periods in 2025. The growth was driven by increased demand for allogenic biologic products in Florida, expanded physician adoption, and stronger commercial momentum across its regenerative biologics portfolio. The company also improved its operating performance, reducing its net loss to approximately $1.0 million from $2.6 million while maintaining gross margins of approximately 80%.